Clinical Research Directory

Inclusion Criteria: 1. Male subjects ≥ 18 years old 2. Subject diagnosed with a recurrent stricture ≤3cm in the anterior urethra that plans to be treated with Optilume® DCB in accordance with the approved Instructions for Use. 3. Subject provides written informed consent using an approved Informed Consent Form (ICF) and is willing to comply with standard follow-up assessments. Exclusion Criteria: 1. Subjects with a known hypersensitivity to paclitaxel or structurally related compounds. 2. Subject is unwilling to abstain or use a condom for 30 days after the procedure. 3. Subject is unwilling to use highly effective contraception for 6 months after the procedure if partner is of childbearing potential. 4. Subjects with a history of carcinoma of the genitourinary system (e.g., kidney, bladder, prostate, urethra, testes) that is not considered in complete remission.